AU2020341479B2 - Methods and compositions for genomic integration - Google Patents
Methods and compositions for genomic integrationInfo
- Publication number
- AU2020341479B2 AU2020341479B2 AU2020341479A AU2020341479A AU2020341479B2 AU 2020341479 B2 AU2020341479 B2 AU 2020341479B2 AU 2020341479 A AU2020341479 A AU 2020341479A AU 2020341479 A AU2020341479 A AU 2020341479A AU 2020341479 B2 AU2020341479 B2 AU 2020341479B2
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- cell
- human
- orf2p
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2026203916A AU2026203916A1 (en) | 2019-09-03 | 2026-05-20 | Methods and compositions for genomic integration |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895441P | 2019-09-03 | 2019-09-03 | |
| US62/895,441 | 2019-09-03 | ||
| US201962908800P | 2019-10-01 | 2019-10-01 | |
| US62/908,800 | 2019-10-01 | ||
| US202063039261P | 2020-06-15 | 2020-06-15 | |
| US63/039,261 | 2020-06-15 | ||
| PCT/US2020/049240 WO2021046243A2 (en) | 2019-09-03 | 2020-09-03 | Methods and compositions for genomic integration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026203916A Division AU2026203916A1 (en) | 2019-09-03 | 2026-05-20 | Methods and compositions for genomic integration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020341479A1 AU2020341479A1 (en) | 2022-03-31 |
| AU2020341479B2 true AU2020341479B2 (en) | 2026-02-26 |
Family
ID=74853338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020341479A Active AU2020341479B2 (en) | 2019-09-03 | 2020-09-03 | Methods and compositions for genomic integration |
| AU2026203916A Pending AU2026203916A1 (en) | 2019-09-03 | 2026-05-20 | Methods and compositions for genomic integration |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026203916A Pending AU2026203916A1 (en) | 2019-09-03 | 2026-05-20 | Methods and compositions for genomic integration |
Country Status (12)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| KR20230091894A (ko) | 2020-10-21 | 2023-06-23 | 메사추세츠 인스티튜트 오브 테크놀로지 | 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| CN112708636A (zh) * | 2021-01-22 | 2021-04-27 | 彭双红 | 基因转录框架、载体系统、基因组序列编辑方法及应用 |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| WO2022241029A1 (en) * | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| CN118119704A (zh) * | 2021-09-08 | 2024-05-31 | 宏基因组学公司 | 用于转座货物核苷酸序列的系统和方法 |
| KR20240051994A (ko) * | 2021-09-08 | 2024-04-22 | 메타지노미, 인크. | 레트로트랜스포존 및 이의 기능적 단편을 포함하는 시스템, 조성물, 및 방법 |
| AU2023240827A1 (en) * | 2022-03-21 | 2024-07-18 | Bio Adventure Co., Ltd. | Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression |
| CN115044583B (zh) * | 2022-03-21 | 2026-06-26 | 隋云鹏 | 用于基因编辑的rna框架和基因编辑方法 |
| WO2024020114A2 (en) * | 2022-07-20 | 2024-01-25 | Addition Therapeutics | Genome insertions in cells |
| WO2024044767A2 (en) * | 2022-08-25 | 2024-02-29 | The Board Of Trustees Of The Leland Stanford Junior University | Recruitment of donor dna from in vivo assembled plasmids for saturation genome editing |
| WO2024102703A2 (en) * | 2022-11-07 | 2024-05-16 | The Regents Of The University Of California | Zikv-based gene delivery system |
| US20260166138A1 (en) * | 2022-11-28 | 2026-06-18 | Yale University | Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox |
| EP4627071A1 (en) * | 2022-12-02 | 2025-10-08 | Averna Therapeutics Ltd | Recombinant proteins comprising non-ltr retrotransposon-derived polypeptides for gene delivery and insertion |
| WO2024131786A1 (zh) * | 2022-12-19 | 2024-06-27 | 北京干细胞与再生医学研究院 | 一种在基因组插入大片段dna的系统 |
| WO2024137392A1 (en) * | 2022-12-22 | 2024-06-27 | Genscript Usa Inc. | Method of preparing self-circularized rna |
| WO2024163805A1 (en) * | 2023-02-01 | 2024-08-08 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| WO2024193739A1 (en) * | 2023-03-23 | 2024-09-26 | Ostravska Univerzita | Method for producing proteins in host cells |
| WO2024220409A1 (en) * | 2023-04-17 | 2024-10-24 | Massachusetts Institute Of Technology | Genomic editing with site-specific retrotransposons |
| EP4780975A1 (en) * | 2023-09-19 | 2026-07-29 | Icahn School of Medicine at Mount Sinai | Bat-associated reverse transcriptase and methods of use thereof |
| WO2025074310A2 (en) * | 2023-10-06 | 2025-04-10 | Exsilio Therapeutics Ltd | Engineered retrotransposable element proteins for gene delivery and insertion |
| AU2024398461A1 (en) * | 2023-12-11 | 2026-07-02 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| CN117899207A (zh) * | 2023-12-12 | 2024-04-19 | 中国医学科学院医学生物学研究所 | 一种轮状病毒mRNA疫苗及其制备方法和应用 |
| WO2025213067A2 (en) * | 2024-04-05 | 2025-10-09 | Arc Research Institute | Methods and compositions for increased expression of integration deficient viral vectors |
| WO2025217194A1 (en) * | 2024-04-09 | 2025-10-16 | Typewriter Therapeutics, Inc. | Repeat dosing of retrotransposons |
| WO2025229499A1 (en) * | 2024-04-29 | 2025-11-06 | Averna Therapeutics Ltd | Compositions and methods for modulating t cells |
| CN121718524A (zh) * | 2024-09-23 | 2026-03-24 | 隋云鹏 | 一种核酸编辑系统及核酸编辑方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110045591A1 (en) * | 2007-10-31 | 2011-02-24 | Bundesrepublik Deutschland, Letztvertreten Durch de Prasidenten des Paul-Ehrlich-Instituts Prof. | Controlled Activation of Non-LTR Retrotransposons in Mammals |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
| FR2709309B1 (fr) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5641863A (en) | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
| US20030121063A1 (en) * | 1995-11-16 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods of use of mammalian retrotransposons |
| US6150160A (en) * | 1995-11-16 | 2000-11-21 | The John Hopkins University | Compositions and methods of use of mammalian retrotransposons |
| US6576463B1 (en) | 1999-01-15 | 2003-06-10 | The Regents Of The University Of California | Hybrid vectors for gene therapy |
| WO2001030965A2 (en) | 1999-10-28 | 2001-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
| US7176243B2 (en) | 2000-06-02 | 2007-02-13 | The General Hospital Corporation | CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| US20060183226A1 (en) * | 2002-01-31 | 2006-08-17 | Haruhiko Fujiwara | Methods for retrotransposing long interspersed elements (lines) |
| AU2003219805B2 (en) | 2002-02-15 | 2009-06-04 | Eisai Inc. | Electroporation methods for introducing bioactive agents into cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| CA2488328C (en) | 2002-06-05 | 2017-03-07 | Kevin L. Rozwadowski | Retrons for gene targeting |
| AU2003241252A1 (en) | 2002-06-06 | 2003-12-22 | Immunicum Ab | New method and composition for producing a cellular allogeneic vaccine |
| US20060239962A1 (en) | 2002-12-04 | 2006-10-26 | Banchereau Jacques F | Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors |
| US20070037759A1 (en) * | 2003-02-07 | 2007-02-15 | Administrators Of The Tulane Educational Fund, The | Mammalian retrotransposable elements |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US8198020B2 (en) | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| US8252587B2 (en) | 2004-10-25 | 2012-08-28 | Celerant Therapeutics, Inc. | Methods of expanding myeloid cell populations and uses thereof |
| GB2421948A (en) | 2004-12-30 | 2006-07-12 | Ist Superiore Sanita | Retrotransposon inhibition to treat cancer |
| US20060188891A1 (en) | 2005-02-23 | 2006-08-24 | Bickmore William D Jr | Methods and apparatus for controlling DNA amplification |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| EP2004237A1 (en) | 2006-04-03 | 2008-12-24 | Keele University | Targeted therapy |
| WO2007130543A2 (en) * | 2006-05-04 | 2007-11-15 | Abmaxis Inc. | Method for producing stable mammalian cell lines producing high levels of recombinant proteins |
| WO2008011599A2 (en) | 2006-07-20 | 2008-01-24 | Gourmetceuticals, Llc | Phosphorylated glucomannan polysaccharide for receptor mediated activation and maturation of monocyte-derived dendritic cells |
| US7833789B2 (en) | 2006-08-01 | 2010-11-16 | Fondazione Centro San Raffaele Del Monte Tabor | Monocyte cell |
| CN1951499A (zh) | 2006-10-09 | 2007-04-25 | 中国农业大学 | 一种细胞免疫疫苗及其制备方法 |
| US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| US9034325B2 (en) | 2008-07-22 | 2015-05-19 | Ablynx N.V. | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| US20110250203A1 (en) | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
| US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
| EP2248903A1 (en) * | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
| JP5975983B2 (ja) | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 固形腫瘍を処置するための方法 |
| WO2012005763A1 (en) | 2010-07-06 | 2012-01-12 | The Scripps Research Institute | Use of myeloid-like progenitor cell populations to treat tumors |
| WO2012043651A1 (ja) | 2010-09-30 | 2012-04-05 | 国立大学法人 熊本大学 | ミエロイド系血液細胞の製造方法 |
| US9206479B2 (en) | 2011-02-09 | 2015-12-08 | University Of Rochester | Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements |
| WO2012133947A1 (en) | 2011-03-30 | 2012-10-04 | Riken | Functional nucleic acid molecule and use thereof |
| EP2753345B1 (en) | 2011-09-06 | 2016-07-13 | Agency For Science, Technology And Research | Polypeptide vaccine |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| US9149519B2 (en) | 2012-01-17 | 2015-10-06 | New York University | Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| ME03512B (me) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2753365B1 (en) | 2012-02-14 | 2017-03-22 | Loma Linda University | Agents for treating inflammation-related conditions and diseases |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| EP2639313A1 (en) | 2012-03-14 | 2013-09-18 | Rheinische Friedrich-Wilhelms-Universität Bonn | High-resolution transcriptome of human macrophages |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| PT2692865E (pt) | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
| US20140037606A1 (en) | 2012-08-06 | 2014-02-06 | Eyal Amiel | Cell-based, anti-cancer vaccines |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| WO2014121840A1 (en) | 2013-02-07 | 2014-08-14 | Medizinische Hochschule Hannover | Induced dendritic cells and uses thereof |
| SE537429C2 (sv) | 2013-02-14 | 2015-04-28 | Scania Cv Ab | Samtidig skattning av åtminstone massa och rullmotstånd förett fordon |
| WO2014134412A1 (en) | 2013-03-01 | 2014-09-04 | Regents Of The University Of Minnesota | Talen-based gene correction |
| US20160145348A1 (en) | 2013-03-14 | 2016-05-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| US20160250258A1 (en) | 2013-10-31 | 2016-09-01 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| US20170233452A1 (en) | 2014-04-23 | 2017-08-17 | Immusoft Corporation | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
| CN104004095B (zh) | 2014-06-04 | 2016-11-23 | 博生吉医药科技(苏州)有限公司 | 一种cd7纳米抗体、其编码序列及应用 |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016016343A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016030501A1 (en) * | 2014-08-28 | 2016-03-03 | Centre National De La Recherche Scientifique - Cnrs - | Synthetic alu-retrotransposon vectors for gene therapy |
| WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| WO2016038168A1 (en) | 2014-09-10 | 2016-03-17 | Miltenyi Biotec Gmbh | A cell population for use in treting cancer |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| MA41538A (fr) | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| CN122564053A (zh) | 2014-10-31 | 2026-08-14 | 麻省理工学院 | 递送生物分子至免疫细胞 |
| WO2016081423A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| US11041158B2 (en) | 2014-12-22 | 2021-06-22 | AgBiome, Inc. | Optimization methods for making a synthetic gene |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| HRP20220890T1 (hr) | 2015-02-06 | 2022-10-14 | National University Of Singapore | Postupci za povećanje učinkovitosti terapijskih imunosnih stanica |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| EP3262166A4 (en) | 2015-02-24 | 2018-08-15 | The Regents of The University of California | Binding-triggered transcriptional switches and methods of use thereof |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| CN107708710A (zh) | 2015-03-17 | 2018-02-16 | 嵌合体生物工程公司 | Smart CAR装置,DE CAR多肽,Side CAR及其使用 |
| WO2016156557A1 (en) * | 2015-04-03 | 2016-10-06 | Alienor Farma | Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
| MA41962A (fr) | 2015-04-23 | 2018-02-28 | Baylor College Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
| DK3298043T3 (da) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| US10434153B1 (en) | 2015-05-20 | 2019-10-08 | Kim Leslie O'Neill | Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors |
| WO2016196612A1 (en) | 2015-06-01 | 2016-12-08 | The Rockefeller University | Anti-tumor agents and methods of use |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
| JP7032304B2 (ja) | 2015-07-28 | 2022-03-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体を発現する改変された単球/マクロファージおよびその使用 |
| AU2016303497A1 (en) | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| SG10201913151TA (en) | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| EP3653717B1 (en) | 2015-09-16 | 2022-11-09 | T-CURX GmbH | Improved transposon system for gene delivery |
| AU2016325384B2 (en) | 2015-09-22 | 2021-07-22 | Julius-Maximilians-Universitat Wurzburg | A method for high level and stable gene transfer in lymphocytes |
| CN105154473B (zh) | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合系统及其用途 |
| EP3334764A2 (en) | 2015-10-13 | 2018-06-20 | Brigham Young University | Macrophage chimeric antigen receptor (moto-car) in imunotherapy |
| WO2017083441A1 (en) | 2015-11-09 | 2017-05-18 | Aperisys, Inc. | Modified immune cells and uses thereof |
| US10946042B2 (en) | 2015-12-01 | 2021-03-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for selective phagocytosis of human cancer cells |
| EP3202783A1 (en) | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| WO2017136633A1 (en) | 2016-02-04 | 2017-08-10 | Duke University | Cell-based vaccine compositions and methods of use |
| WO2017133175A1 (en) | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| GB201602473D0 (en) | 2016-02-11 | 2016-03-30 | Horizon Discovery Ltd | Replicative transposon system |
| US20170275665A1 (en) | 2016-02-24 | 2017-09-28 | Board Of Regents, The University Of Texas System | Direct crispr spacer acquisition from rna by a reverse-transcriptase-cas1 fusion protein |
| US10617749B1 (en) | 2016-02-24 | 2020-04-14 | Duke University | Composition of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy |
| US20200063157A9 (en) | 2016-02-26 | 2020-02-27 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| EP3219803A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum für Molekulare Medizin | Enhanced sleeping beauty transposons, kits and methods of transposition |
| WO2019055946A1 (en) | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| US20180186855A1 (en) | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017184553A1 (en) | 2016-04-18 | 2017-10-26 | Baylor College Of Medicine | Cancer gene therapy targeting cd47 |
| US10875919B2 (en) | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| US11390658B2 (en) | 2016-06-06 | 2022-07-19 | St. Jude Children's Research Hospital | Anti-CD7 chimeric antigen receptor and method of use thereof |
| US11130951B2 (en) | 2016-06-09 | 2021-09-28 | The General Hospital Corporation | Modulating the cellular stress response |
| AU2017283713B2 (en) | 2016-06-17 | 2021-04-08 | Massachusetts Institute Of Technology | Type VI CRISPR orthologs and systems |
| CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| EP3504244A4 (en) | 2016-08-26 | 2020-08-19 | Agency for Science, Technology and Research | MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| EP3518944A4 (en) | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| US11376332B2 (en) | 2016-10-15 | 2022-07-05 | Baylor College Of Medicine | Platform for enhanced targeted delivery |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| WO2018089860A1 (en) | 2016-11-11 | 2018-05-17 | 2D Genomics Inc. | Methods for processing nucleic acid samples |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| KR102993694B1 (ko) | 2016-12-09 | 2026-07-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| KR102708285B1 (ko) | 2017-03-13 | 2024-09-20 | 포세이다 테라퓨틱스, 인크. | 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법 |
| CN111108220B (zh) | 2017-03-15 | 2024-11-19 | 博德研究所 | 用于病毒检测的基于crispr效应系统的诊断 |
| US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| CA3067244A1 (en) | 2017-06-12 | 2018-12-20 | Children's Healthcare Of Atlanta, Inc. | T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies |
| TW201904588A (zh) | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| WO2019010551A1 (pt) | 2017-07-10 | 2019-01-17 | Instituto De Biologia Molecular Do Paraná - Ibmp | Plataforma genética para superexpressão heteróloga associada à seleção de células altamente produtoras de proteínas |
| WO2019023164A1 (en) | 2017-07-24 | 2019-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | COMPOSITIONS AND METHODS FOR INDUCING PROTEIN FUNCTION |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| CN109306340B (zh) | 2017-07-27 | 2023-06-06 | 上海细胞治疗研究院 | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 |
| CN109337872B (zh) | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| EP3664845A4 (en) | 2017-08-08 | 2021-03-10 | Pionyr Immunotherapeutics, Inc. | COMPOSITIONS AND METHODS OF DEACTIVATION OF MYELOID CELLS EXPRESSING TREM1 |
| WO2019050948A1 (en) | 2017-09-05 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING |
| JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス,インコーポレイティド | キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法 |
| DK3688032T3 (da) | 2017-09-26 | 2025-12-15 | Cero Therapeutics Holdings Inc | Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder |
| US12467050B2 (en) | 2017-10-02 | 2025-11-11 | Georgia Tech Research Corporation | Methods and compositions for engineering synthetic bioswitches for remote control of biological activity |
| WO2019070843A1 (en) | 2017-10-03 | 2019-04-11 | Board Of Regents, The University Of Texas System | INVERSE TRANSCRIPTASE WITH LTR-FREE BACKLIGHTS AND USES THEREOF |
| JP7395483B2 (ja) | 2017-10-16 | 2023-12-11 | アーディジェン, エルエルシー | mRNAの細胞内送達のためのペプチドおよびナノ粒子 |
| GB201717974D0 (en) | 2017-10-31 | 2017-12-13 | Univ Court Of The Univ Of Aberdeen | Modified receptors |
| US20200255829A1 (en) | 2017-11-02 | 2020-08-13 | Arbor Biotechnologies, Inc. | Novel crispr-associated transposon systems and components |
| CN109971716B (zh) | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| CA3092832A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh loci |
| GB2572005A (en) | 2018-03-16 | 2019-09-18 | Univ Court Univ Of Edinburgh | Macrophage-based therapy |
| WO2019191332A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| RU2020135107A (ru) | 2018-03-28 | 2022-04-29 | Серо Терапьютикс, Инк. | Клеточные иммунотерапевтические композиции и их применения |
| SG11202011240YA (en) | 2018-06-26 | 2020-12-30 | Broad Inst Inc | Crispr/cas and transposase based amplification compositions, systems and methods |
| WO2020014303A1 (en) | 2018-07-11 | 2020-01-16 | X Gen Us Co. | Transposome enabled dna/rna-sequencing (ted rna-seq) |
| JP2021530212A (ja) | 2018-07-13 | 2021-11-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | レトロトランスポゾンベースの送達媒体及びその使用方法 |
| AU2019327449B2 (en) | 2018-08-28 | 2026-04-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| EP3628309A1 (en) | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| GB201818110D0 (en) | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| WO2020131662A1 (en) | 2018-12-19 | 2020-06-25 | Amgen Inc. | Apparatus for resolving imaging problems caused by the meniscus |
| KR20210116526A (ko) * | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US20220378824A1 (en) | 2019-04-30 | 2022-12-01 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| US20220001031A1 (en) | 2019-04-30 | 2022-01-06 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| AU2020266595A1 (en) | 2019-04-30 | 2021-11-25 | Create Medicines, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| GB2603044B (en) | 2019-06-11 | 2024-08-21 | Myeloid Therapeutics Inc | Macrophage specific engager compositions and methods of use thereof |
| AU2020296190A1 (en) | 2019-06-19 | 2022-01-06 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
| CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US20230040216A1 (en) | 2019-11-19 | 2023-02-09 | The Broad Institute, Inc. | Retrotransposons and use thereof |
| MX2022007107A (es) | 2019-12-11 | 2022-11-14 | Myeloid Therapeutics Inc | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| AU2021232005A1 (en) | 2020-03-04 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| IL296095A (en) | 2020-03-04 | 2022-11-01 | Flagship Pioneering Innovations Vi Llc | Improved methods and compositions for genome modulation |
| BR112022017735A2 (pt) | 2020-03-05 | 2022-11-29 | Flagship Pioneering Innovations Vi Llc | Métodos e composições de supressão de defesa de hospedeiro para modular um genoma |
| KR20230091894A (ko) | 2020-10-21 | 2023-06-23 | 메사추세츠 인스티튜트 오브 테크놀로지 | 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| WO2023039221A2 (en) | 2021-09-10 | 2023-03-16 | Myeloid Therapeutics, Inc. | Macrophage specific engager compositions and methods of use thereof |
| AU2024398461A1 (en) | 2023-12-11 | 2026-07-02 | Create Medicines, Inc. | Methods and compositions for genomic integration |
-
2020
- 2020-09-03 WO PCT/US2020/049240 patent/WO2021046243A2/en not_active Ceased
- 2020-09-03 MX MX2022002613A patent/MX2022002613A/es unknown
- 2020-09-03 GB GB2409022.7A patent/GB2628935B/en active Active
- 2020-09-03 CN CN202080077028.9A patent/CN114981409A/zh active Pending
- 2020-09-03 EP EP20861388.5A patent/EP4025686A4/en active Pending
- 2020-09-03 GB GB2203647.9A patent/GB2605276B/en active Active
- 2020-09-03 CA CA3149897A patent/CA3149897A1/en active Pending
- 2020-09-03 JP JP2022514694A patent/JP7831937B2/ja active Active
- 2020-09-03 KR KR1020227010704A patent/KR20220097875A/ko active Pending
- 2020-09-03 BR BR112022003970A patent/BR112022003970A2/pt unknown
- 2020-09-03 AU AU2020341479A patent/AU2020341479B2/en active Active
-
2021
- 2021-10-12 US US17/499,232 patent/US11672874B2/en active Active
-
2022
- 2022-03-02 IL IL291048A patent/IL291048A/en unknown
- 2022-03-04 US US17/687,395 patent/US20220184230A1/en active Pending
- 2022-06-30 US US17/855,230 patent/US20220364110A1/en not_active Abandoned
- 2022-06-30 US US17/855,423 patent/US20220411817A1/en not_active Abandoned
-
2023
- 2023-05-05 US US18/313,126 patent/US12599678B2/en active Active
- 2023-05-05 US US18/313,087 patent/US20230364265A1/en active Pending
-
2026
- 2026-02-27 JP JP2026030500A patent/JP2026097901A/ja active Pending
- 2026-05-20 AU AU2026203916A patent/AU2026203916A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110045591A1 (en) * | 2007-10-31 | 2011-02-24 | Bundesrepublik Deutschland, Letztvertreten Durch de Prasidenten des Paul-Ehrlich-Instituts Prof. | Controlled Activation of Non-LTR Retrotransposons in Mammals |
Also Published As
| Publication number | Publication date |
|---|---|
| GB202203647D0 (en) | 2022-04-27 |
| GB2605276A (en) | 2022-09-28 |
| GB202409022D0 (en) | 2024-08-07 |
| EP4025686A2 (en) | 2022-07-13 |
| JP2026097901A (ja) | 2026-06-16 |
| US20230364266A1 (en) | 2023-11-16 |
| AU2026203916A1 (en) | 2026-06-04 |
| MX2022002613A (es) | 2022-06-02 |
| WO2021046243A2 (en) | 2021-03-11 |
| BR112022003970A2 (pt) | 2022-06-21 |
| US12599678B2 (en) | 2026-04-14 |
| IL291048A (en) | 2022-05-01 |
| US20230364265A1 (en) | 2023-11-16 |
| US20230067484A1 (en) | 2023-03-02 |
| GB2628935A (en) | 2024-10-09 |
| JP7831937B2 (ja) | 2026-03-17 |
| GB2605276B (en) | 2024-08-07 |
| GB2628935B (en) | 2025-03-05 |
| US20220411817A1 (en) | 2022-12-29 |
| WO2021046243A9 (en) | 2022-06-23 |
| US20220364110A1 (en) | 2022-11-17 |
| US11672874B2 (en) | 2023-06-13 |
| US20220184230A1 (en) | 2022-06-16 |
| EP4025686A4 (en) | 2023-09-13 |
| WO2021046243A3 (en) | 2021-06-03 |
| KR20220097875A (ko) | 2022-07-08 |
| JP2022546592A (ja) | 2022-11-04 |
| CA3149897A1 (en) | 2021-03-11 |
| CN114981409A (zh) | 2022-08-30 |
| AU2020341479A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12599678B2 (en) | Methods and compositions for genomic integration | |
| KR102729768B1 (ko) | 트랜스제닉 선택 방법 및 조성물 | |
| AU2019252285B2 (en) | Viral vectors and packaging cell lines | |
| AU774643B2 (en) | Compositions and methods for use in recombinational cloning of nucleic acids | |
| RU2718536C2 (ru) | Способы получения и применения популяций мультипотентных и плюрипотентных клеток, устойчивых к заболеваниям и способных к дифференцировке | |
| KR20240037192A (ko) | 게놈 통합을 위한 방법 및 조성물 | |
| AU2014372562B2 (en) | A method of making adenovirus and corresponding plasmids | |
| CN115323000B (zh) | 使用细胞分裂基因座控制细胞增殖的工具和方法 | |
| KR20240004253A (ko) | 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법 | |
| KR20210151785A (ko) | 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도 | |
| KR20240022575A (ko) | 아머링된 키메라 수용체 및 이의 사용 방법 | |
| CN115666722A (zh) | 包封的rna复制子和使用方法 | |
| KR20200085812A (ko) | 바이러스 벡터-유도된 염증 반응을 억제하기 위한 조성물 및 방법 | |
| CN116323942A (zh) | 用于基因组编辑的组合物及其使用方法 | |
| WO2024163805A1 (en) | Methods and compositions for genomic integration | |
| NL2027815B1 (en) | Genomic integration | |
| RU2812852C2 (ru) | Невирусные днк-векторы и варианты их применения для экспрессии терапевтического средства на основе фактора viii (fviii) | |
| HK40082332A (zh) | 使用细胞分裂基因座控制细胞增殖的工具和方法 | |
| HK40082332B (en) | Tools and methods for using cell division loci to control proliferation of cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO CREATE MEDICINES, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |